Rabbit RPS6KA3 Polyclonal Antibody | anti-RPS6KA3 antibody

RPS6KA3 (ISPK1, MAPKAPK1B, RSK2, Ribosomal protein S6 kinase alpha-3, 90kD ribosomal protein S6 kinase 2, Insulin-stimulated protein kinase 1, MAP kinase-activated protein kinase 1b, Ribosomal S6 kinase 2, pp90RSK2)

Cat. Num. AAA647636

• Gene Names: RPS6KA3; CLS; RSK; HU-3; RSK2; MRX19; ISPK-1; p90-RSK2; pp90RSK2; MAPKAPK1B; S6K-alpha3
• Reactivity: Bovine, Canine, Chicken, Human, Mouse, Rat
• Applications: Western Blot, Immunohistochemistry
• Purity: Affinity Purified; Purified by immunoaffinity chromatography
• Synonyms: RPS6KA3; Polyclonal Antibody; RPS6KA3 (ISPK1; MAPKAPK1B; RSK2; Ribosomal protein S6 kinase alpha-3; 90kD ribosomal protein S6 kinase 2; Insulin-stimulated protein kinase 1; MAP kinase-activated protein kinase 1b; Ribosomal S6 kinase 2; pp90RSK2); Anti -RPS6KA3 (ISPK1; anti-RPS6KA3 antibody

• Host: Rabbit
• Reactivity: Bovine, Canine, Chicken, Human, Mouse, Rat
• Clonality: Polyclonal
• Specificity: Recognizes rat RPS6KA3/RSK2. Species Crossreactivity: Bovine, canine, chicken, human, mouse, rat.
• Purity/Purification: Affinity Purified; Purified by immunoaffinity chromatography
• Form/Format: Supplied as a liquid in HEPES (pH 7.5), 150mM NaCl, 100ug per ml BSA, 50% glycerol.

• Applicable Applications for anti-RPS6KA3 antibody: Western Blot (WB), Immunohistochemistry (IHC)
• Application Notes: Suitable for use in Western Blot and Immunohistochemistry.; Dilution: Western Blot: 1:1000; Immunohistochemistry (Paraffin): 1:100
• Immunogen: Synthetic peptide corresponding to rat RPS6KA3/RSK2 at C-Terminal (KLH).
• Preparation and Storage: May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Immunohistochemistry (IHC)

(Human Placenta: Formalin-Fixed, Paraffin-Embedded (FFPE))

Western Blot (WB)

(Western blot of HeLa cell lysate showing specific immunolabeling of the ~90k RSK2 protein. Summary: RSK2, an RSK serine)

Related Product Information for anti-RPS6KA3 antibody

RSK2, an RSK serine/threonine kinase, has been implicated in Coffin-Lowry syndrome, a disease characterized by cognitive impairment, characteristic facial and digital findings and skeletal anomalies.

Product Categories/Family for anti-RPS6KA3 antibody

Antibodies; Abs to Protein Kinases

NCBI and Uniprot Product Information

• NCBI GI #: 33354095
• NCBI GeneID: 6197
• UniProt Accession #: P51812; Q4VAP3; Q59H26; Q5JPK8; Q7Z3Z7; B2R9V4
• Molecular Weight: 83,736 Da
• NCBI Official Full Name: RPS6KA3
• NCBI Official Synonym Full Names: ribosomal protein S6 kinase, 90kDa, polypeptide 3
• NCBI Official Symbol: RPS6KA3
• NCBI Official Synonym Symbols: CLS; RSK; HU-3; RSK2; MRX19; ISPK-1; p90-RSK2; pp90RSK2; MAPKAPK1B; S6K-alpha3
• NCBI Protein Information: ribosomal protein S6 kinase alpha-3; RSK-2; p90-RSK 3; MAPKAPK-1b; S6K-alpha-3; MAPKAP kinase 1b; ribosomal S6 kinase 2; MAPK-activated protein kinase 1b; insulin-stimulated protein kinase 1; MAP kinase-activated protein kinase 1b
• UniProt Protein Name: Ribosomal protein S6 kinase alpha-3
• Protein Family: Ribosomal protein S6 kinase
• UniProt Gene Name: RPS6KA3
• UniProt Synonym Gene Names: ISPK1; MAPKAPK1B; RSK2; S6K-alpha-3; p90-RSK 3; p90RSK3; ISPK-1; MAPK-activated protein kinase 1b; MAPKAP kinase 1b; MAPKAPK-1b; RSK-2
• UniProt Entry Name: KS6A3_HUMAN

NCBI Description

This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome (CLS). [provided by RefSeq, Jul 2008]

Uniprot Description

Function: Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1. Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.15 Ref.16

Catalytic activity: ATP + a protein = ADP + a phosphoprotein.

Cofactor: Magnesium

By similarity.

Enzyme regulation: Upon extracellular signal or mitogen stimulation, phosphorylated at Thr-577 in the C-terminal kinase domain (CTKD) by MAPK1/ERK2 and MAPK3/ERK1. The activated CTKD then autophosphorylates Ser-386, allowing binding of PDPK1, which in turn phosphorylates Ser-227 in the N-terminal kinase domain (NTDK) leading to the full activation of the protein and subsequent phosphorylation of the substrates by the NTKD.

Subunit structure: Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 in quiescent cells. Transiently dissociates following mitogenic stimulation

By similarity. Interacts with NFATC4, ETV1/ER81 and FGFR1. Ref.14

Subcellular location: Nucleus

By similarity. Cytoplasm

By similarity.

Tissue specificity: Expressed in many tissues, highest levels in skeletal muscle.

Post-translational modification: Activated by phosphorylation at Ser-227 by PDPK1. Autophosphorylated on Ser-386, as part of the activation process. May be phosphorylated at Thr-365 and Ser-369 by MAPK1/ERK2 and MAPK3/ERK1. Can also be activated via phosphorylation at Ser-386 by MAPKAPK2.N-terminal myristoylation results in an activated kinase in the absence of added growth factors.

Involvement in disease: Coffin-Lowry syndrome (CLS) [MIM:303600]: A X-linked mental retardation associated with facial and digital dysmorphisms, progressive skeletal malformations, growth retardation, hearing deficit and paroxysmal movement disorders.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.26 Ref.27 Ref.28 Ref.29 Ref.31 Ref.32Mental retardation, X-linked 19 (MRX19) [MIM:300844]: A non-syndromic form of mild to moderate mental retardation. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. In contrast to syndromic or specific X-linked mental retardation which also present with associated physical, neurological and/or psychiatric manifestations, intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.30 Ref.33

Sequence similarities: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily.Contains 1 AGC-kinase C-terminal domain.Contains 2 protein kinase domains.

Sequence caution: The sequence BAD92170.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.